Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Archexin + Everolimus in Metastatic RCC
NCT02089334Phase 2Terminated
- Sponsor
- Rexahn Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Apr 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Archexin in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Rexahn Pharmaceuticals. Primary endpoints: Incidence of Dose-limiting Toxicities at 3 weeks and Progression Free Survival at 4 months. Started Aug 2014; status: terminated.
02
Drugs
Archexin
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02089334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089334.